Alzheimer's & Dementia

Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills. Alzheimer’s is the most common cause of dementia among older adults. Dementia is the loss of cognitive functioning—thinking, remembering, and reasoning—and behavioral abilities to such an extent that it interferes with a person’s daily life and activities.

GLP-1 Receptor Agonists in Alzheimer’s Disease: Emerging Off-Label Neuroprotective Potential

GLP-1 receptor agonists show strong preclinical neuroprotective potential in Alzheimer’s disease through effects on insulin signaling, neuroinflammation, amyloid, tau, and brain metabolism. Human evidence remains mixed, with observational studies suggesting lower dementia risk but randomized trials yet to demonstrate a clinically meaningful disease-modifying benefit.

Alzheimer's Disease Causes

Mixed Dementia Symptoms and Diagnosis

Alzheimer's Disease Prevention

Stem Cell Therapy for Alzheimer's

Antidepressants and Dementia: Is There a Link?

What is Dementia?

Stress and Alzheimer's Disease

Does Herpesvirus Cause Alzheimer's?

Alzheimer's Disease and Sleep Disruption

Alzheimer's Disease Questions

Alzheimer's and Veganism

See more featured articles »

What are Amyloid Plaques?

What is Mixed Dementia?

Dementia Prevention

Alzheimer's Disease Diagnosis

Childhood Dementia Signs and Symptoms

Integrated PET/MR for Alzheimer’s Disease

What Causes Dementia?

Bright Light Therapy and Dementia

Gender and Alzheimer’s Risk

Parkinson's Compared to Dementia with Lewy Bodies (DLB)

Antibody Research and Alzheimer’s Disease

Does Type 2 Diabetes Increase the Risk of Alzheimer’s Disease?

Alzheimer’s Disease | Definition, Causes, Diagnosis & Treatment

Inflammation and Alzheimer's Disease

Alzheimer’s tangles and plaques: what’s the difference?

Dementia with Lewy Bodies

Transcutaneous Electrical Nerve Stimulation for Dementia

Aromatherapy for Dementia

Mixed Dementia Prevention and Treatment

Can Statins Protect Against Alzheimer’s Disease?

Diet and Alzheimer's Disease

Alzheimer’s Disease and Calcium Supplements

Alzheimer's Disease Symptoms

Childhood Dementia Causes

Alzheimer’s Disease and Gingko Biloba

Alzheimer's Disease and the Microbiome

Dementia Treatment

Alzheimer's Disease Epidemiology

Omega-3 and Alzheimer’s Disease

Dementia Symptoms

Biomarkers for Alzheimer's Disease

Do Antioxidants Benefit Patients with Alzheimer’s and Parkinson’s?

Does Depression and Anxiety Increase the Risk of Dementia?

AAM - Air pollution and Alzheimer's

Differences Between Alzheimer's and Dementia

Dancing Through Dementia: How Movement Aids Memory and Mood

Can Happiness Protect You from Dementia?

Alzheimer's Disease Treatments

Designing Dementia-Friendly Environments

Migraines and Dementia

Does Type 2 Diabetes Increase the Risk of Alzheimer’s Disease?

AAM - Genetics of Alzheimer's

Pollution and Alzheimer's

AAM - The Search for a Cure to Alzheimer's

Amyloid Cascade Hypothesis

Types of Alzheimer's Disease

Dementia Diagnosis

Is Alzheimer's Disease Transmissible?

Coconut Oil and Dementia

Mythbusting: Misconceptions in Dementia

Latest Alzheimer's & Dementia News and Research

Blood pressure intervention lowers dementia risk in community-based trial

In a community-based trial in rural China, an intensive blood-pressure lowering intervention reduced the incidence of dementia compared with usual care, according to results from the China Rural Hypertension Control Program presented in a Hot Line session today at ESC Congress 2026.

30 Aug 2026

Does a psychedelic need an awake brain to have lasting effects? This mouse study offers a clue

A single dose of psilocybin produced a lasting increase in sociability for at least two weeks in Cntnap2-knockout mice with social deficits, while it did not enhance sociability overall in mice with normal social behavior. The effect required 5-HT2A receptor activation and persisted when psilocybin was administered under light anesthesia, suggesting that wakefulness during the drug’s acute effects was not necessary for this behavioral response.

30 Aug 2026

Starting statins early after diabetes diagnosis linked to lower dementia risk

Early initiation of statins after diagnosis of type 2 diabetes was associated with a lower risk of dementia, according to a study presented today at ESC Congress 2026 and published in The Lancet Regional Health – Europe.

30 Aug 2026

People with diabetes may have another reason to protect their cardiovascular health

Better cardiovascular health, measured using Life’s Essential 8, was associated with a lower risk of mild cognitive impairment among people with diabetes after accounting for genetic susceptibility. Associations with dementia varied by genetic risk, while higher LE8 scores were also linked to greater gray matter volume and lower white matter hyperintensity volume.

30 Aug 2026

Atorvastatin reduces major cardiovascular events but misses disability-free survival goal

Atorvastatin reduced major cardiovascular events by 30% in older people without known cardiovascular disease, diabetes or dementia, but did not significantly improve disability-free survival, according to results presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

29 Aug 2026

Primate-specific DNA change reveals a new link to dementia-related neurodegeneration

Brain diseases, including dementia, have long been studied using experimental animals such as mice. However, differences between the human and animal genomes have raised concerns that some disease mechanisms may not be fully explained by conventional animal models.

29 Aug 2026

Blood-brain barrier-crossing blood pressure drugs linked to lower dementia risk

In a large Australian cohort of adults with hypertension, use of blood-brain barrier-crossing antihypertensive medications was associated with a lower risk of dementia and mortality than use of non-crossing drugs. The association was strongest for beta-blockers and angiotensin II receptor blockers, although the observational design means the findings cannot establish causality.

27 Aug 2026

Parkinson’s disease imposes €22.8 billion economic burden across Europe

The annual societal cost of Parkinson's disease across Europe reached €22.8 billion in 2019, equivalent to €28.8 billion at 2025 prices, a new study published today in Movement Disorders has shown.

27 Aug 2026

Study links later-life food insecurity to elevated dementia risk

Older adults who experienced food insecurity in both midlife and later life had nearly four times the risk of probable dementia as those who remained food secure, according to new University of Michigan research.

27 Aug 2026

HRT linked to lower dementia risk, but timing and menopause type matter

In a UK Biobank study of 183,450 postmenopausal women followed for an average of 13.3 years, hormone replacement therapy use was associated with a modestly lower risk of dementia, with stronger associations in women who had surgical menopause or shorter natural estrogen exposure. The relationship also varied by age at HRT initiation, while the observational design means the findings cannot establish that HRT prevents dementia.

27 Aug 2026

Salk researchers isolate specific neurons controlling complex social behaviors

Our brains constantly integrate information about both our internal state and our surroundings to determine how we behave.

27 Aug 2026

Egg yolk peptides protect brain cells from oxidative stress

As the human lifespan increases, so too does the risk of developing neurological disorders such as Parkinson's disease, Alzheimer's disease, anxiety and depression.

27 Aug 2026

Brain organoids reveal how Alu-mediated gene deletion can lead to neurodegeneration

Brain diseases, including dementia, have long been studied using experimental animals such as mice.

27 Aug 2026

Multi-ancestry genetic score improves risk prediction for Alzheimer's disease

Late-onset Alzheimer disease (AD) is a progressive disorder characterized by cognitive decline and memory impairment, affecting an estimated 6.9 million people in the U.S.

27 Aug 2026

Brain shrinkage biomarker may predict early-onset Alzheimer’s progression

In people diagnosed with early-onset Alzheimer's disease, a biomarker tool that detects shrinkage of the brain's gray matter may predict how quickly someone may progress from mild cognitive impairment (MCI) to dementia, according to a new study published August 26, 2026, in Neurology, an official journal of the American Academy of Neurology.

27 Aug 2026

Brain atrophy on MRI could help predict Alzheimer’s progression

Mass General Brigham Neuroscience Institute researchers have found that a pattern of brain atrophy visible on MRI could help predict how quickly people with early-onset Alzheimer's disease progress from mild cognitive impairment to dementia.

27 Aug 2026

Faulty myelin-making brain cells may help drive cognitive decline with age

Researchers found that greater age-related cognitive decline was associated with more dysfunctional oligodendrocytes, reduced NRF2 expression, smaller myelinated axons, and abnormally thicker myelin in human white matter. Experiments in mice showed that deleting NRF2 specifically from oligodendrocytes reproduced key white matter abnormalities and reduced cognitive improvement over time, implicating this pathway in cognitive aging.

26 Aug 2026

A major NFL brain study puts new numbers on the burden of CTE

Researchers analyzed 1,712 former NFL players who died between 2008 and 2021, including 338 brain donors, to estimate the possible prevalence of chronic traumatic encephalopathy (CTE) at death and its association with dementia. At least 24.5% of players who died from 2016 to 2021 had confirmed CTE, while stage IV CTE among brain donors was associated with a 44% higher risk of clinician-adjudicated dementia.

26 Aug 2026